Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Thomas OG"'
Autor:
Jensen, Dennis M, Ohning, Gordon V, Kovacs, Thomas OG, Ghassemi, Kevin A, Jutabha, Rome, Dulai, Gareth S, Machicado, Gustavo A
Publikováno v:
Gastrointestinal endoscopy, vol 83, iss 1
Background and aimsFor more than 4 decades endoscopists have relied on ulcer stigmata for risk stratification and as a guide to hemostasis. None used arterial blood flow underneath stigmata to predict outcomes. For patients with severe peptic ulcer b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::cab6312d2485cd3803bb970933e67139
https://escholarship.org/uc/item/1465f611
https://escholarship.org/uc/item/1465f611
Autor:
Sheetal Sawant, Sarah Anne Gurley, R. Glenn Overman, Angelina Sharak, Sarah V. Mudrak, Thomas Oguin, Gregory D. Sempowski, Marcella Sarzotti-Kelsoe, Emmanuel B. Walter, Hang Xie, Marcela F. Pasetti, M. Anthony Moody, Georgia D. Tomaras
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionHemagglutination inhibition (HAI) antibody titers to seasonal influenza strains are important surrogates for vaccine-elicited protection. However, HAI assays can be variable across labs, with low sensitivity across diverse viruses due to
Externí odkaz:
https://doaj.org/article/fb09ca27495b4849a863aa424e95e29c
Autor:
Thomas Ogao Onchuru, Martin Kaltenpoth
Publikováno v:
Ecology and Evolution, Vol 9, Iss 14, Pp 8187-8192 (2019)
Abstract RNA interference (RNAi) is a powerful tool for studying functions of candidate genes in both model and nonmodel organisms and a promising technique for therapeutic applications. Successful application of this technique relies on the accuracy
Externí odkaz:
https://doaj.org/article/a0bb8bdd181f49eb91bcb6b1d5ac2c78
Autor:
Yvonne Ukamaka Ajamma, Thomas Ogao Onchuru, Daniel O Ouso, David Omondi, Daniel K Masiga, Jandouwe Villinger
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 12, Iss 11, p e0006949 (2018)
BackgroundMany arboviruses transmitted by mosquitoes have been implicated as causative agents of both human and animal illnesses in East Africa. Although epidemics of arboviral emerging infectious diseases have risen in frequency in recent years, the
Externí odkaz:
https://doaj.org/article/4c22e91cc65b44af83993acbf92a1302
Autor:
Sadiki Materu, Helen S. Cox, Petros Isaakidis, Bienvenu Baruani, Thomas Ogaro, Dominique A. Caugant
Publikováno v:
Emerging Infectious Diseases, Vol 13, Iss 6, Pp 944-945 (2007)
Externí odkaz:
https://doaj.org/article/808068b9fe2b44f0b600a4b4f5d6a846
Autor:
Marti Z; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.; Research and Development, Cellerys, Schlieren, Switzerland.; Department of Neuroimmunology and Multiple Sclerosis Research, University Hospital Zurich, Zurich, Switzerland., Ruder J; Department of Neuroimmunology and Multiple Sclerosis Research, University Hospital Zurich, Zurich, Switzerland., Thomas OG; Therapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden., Bronge M; Therapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.; Department of Neurology, Karolinska University Hospital, Stockholm, Sweden., De La Parra Soto L; Therapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.; Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden., Grönlund H; Therapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden., Olsson T; Neuroimmunology Unit, Department of Clinical Neurocience, Karolinska Institutet, Stockholm, Sweden., Martin R; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.; Research and Development, Cellerys, Schlieren, Switzerland.; Department of Neuroimmunology and Multiple Sclerosis Research, University Hospital Zurich, Zurich, Switzerland.; Therapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Publikováno v:
Frontiers in immunology [Front Immunol] 2024 Aug 27; Vol. 15, pp. 1334720. Date of Electronic Publication: 2024 Aug 27 (Print Publication: 2024).
Autor:
Thomas OG; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, United Kingdom., Haigh TA; Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, United Kingdom., Croom-Carter D; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, United Kingdom., Leese A; School of Biological Sciences, University of Birmingham, Edgbaston, United Kingdom., Van Wijck Y; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, United Kingdom., Douglas MR; Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom.; Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom., Rickinson A; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, United Kingdom., Brooks JM; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, United Kingdom., Taylor GS; Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, United Kingdom.
Publikováno v:
PLoS pathogens [PLoS Pathog] 2024 Jun 06; Vol. 20 (6), pp. e1012177. Date of Electronic Publication: 2024 Jun 06 (Print Publication: 2024).
Autor:
Rabenstein M; Therapeutic Immune Design, Department of Clinical Neuroscience, Center for Molecular Medicine L8:02, Karolinska Institute, Stockholm, Sweden.; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine L8:04, Karolinska Institute, Stockholm, Sweden.; Department of Neurology, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany., Thomas OG; Therapeutic Immune Design, Department of Clinical Neuroscience, Center for Molecular Medicine L8:02, Karolinska Institute, Stockholm, Sweden.; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine L8:04, Karolinska Institute, Stockholm, Sweden., Carlin G; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine L8:04, Karolinska Institute, Stockholm, Sweden., Khademi M; Therapeutic Immune Design, Department of Clinical Neuroscience, Center for Molecular Medicine L8:02, Karolinska Institute, Stockholm, Sweden., Högelin KA; Therapeutic Immune Design, Department of Clinical Neuroscience, Center for Molecular Medicine L8:02, Karolinska Institute, Stockholm, Sweden., Malmeström C; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Axelsson M; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Brandt AF; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gafvelin G; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine L8:04, Karolinska Institute, Stockholm, Sweden., Grönlund H; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine L8:04, Karolinska Institute, Stockholm, Sweden., Kockum I; Therapeutic Immune Design, Department of Clinical Neuroscience, Center for Molecular Medicine L8:02, Karolinska Institute, Stockholm, Sweden., Piehl F; Therapeutic Immune Design, Department of Clinical Neuroscience, Center for Molecular Medicine L8:02, Karolinska Institute, Stockholm, Sweden., Lycke J; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Olsson T; Therapeutic Immune Design, Department of Clinical Neuroscience, Center for Molecular Medicine L8:02, Karolinska Institute, Stockholm, Sweden., Hessa T; Therapeutic Immune Design, Department of Clinical Neuroscience, Center for Molecular Medicine L8:02, Karolinska Institute, Stockholm, Sweden.; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine L8:04, Karolinska Institute, Stockholm, Sweden.
Publikováno v:
European journal of neurology [Eur J Neurol] 2023 Dec; Vol. 30 (12), pp. 3789-3798. Date of Electronic Publication: 2023 Aug 24.
Autor:
Thomas OG; Therapeutic Immune Design, Centre for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.; Neuroimmunology Unit, Department of Clinical Neuroscience, Centre for Molecular Medicine, Karolinska Institute, Stockholm, Sweden., Olsson T; Therapeutic Immune Design, Centre for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Publikováno v:
Frontiers in immunology [Front Immunol] 2023 Nov 03; Vol. 14, pp. 1304281. Date of Electronic Publication: 2023 Nov 03 (Print Publication: 2023).
Autor:
Thomas OG; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden., Bronge M; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden., Tengvall K; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, 171 76 Stockholm, Sweden.; Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, 75123 Uppsala, Sweden., Akpinar B; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden., Nilsson OB; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden., Holmgren E; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden., Hessa T; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden., Gafvelin G; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden., Khademi M; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, 171 76 Stockholm, Sweden., Alfredsson L; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, 171 76 Stockholm, Sweden.; Institute of Environmental Medicine, Karolinska Institute, 171 77 Stockholm, Sweden., Martin R; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.; Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland., Guerreiro-Cacais AO; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, 171 76 Stockholm, Sweden., Grönlund H; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden., Olsson T; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, 171 76 Stockholm, Sweden., Kockum I; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, 171 76 Stockholm, Sweden.
Publikováno v:
Science advances [Sci Adv] 2023 May 19; Vol. 9 (20), pp. eadg3032. Date of Electronic Publication: 2023 May 17.